In Patients With Extensive Stage SMALL CELL LUNG CÁNCER (ES-SCLC), Treatment Options Are Limited Following Progression From anti-PD-L1 Therapy And Chemotherapy .
Andrea Ardizzoni, MD, PhD, University of Bologna, Bologna, Italy, Discusses Findings From The TROPiCS-03 Study (NCT03964727) Where SACITUZUMAB GOVITECAN Showed Promise as a SECOND-LINE Treatment For Patients With ES-SCLC .
Among 26 Patients, The Preliminary Results Revealed a 29% Objective Response Rate And a 36% Clinical Benefit Rate As Well As a Manageable Safety Profile Suggesting The Potencial For SACITUZUMAB GOVITECAN In This Challenging Setting .
This Interview Took Place At The European Society For Medical Oncology (ESMO) 2023 Congress in Madrid, Spain . ...
